EN English (IN) ENEnglish ENEnglish (UK) DEDeutsch FRFrançais ESEspañol ITItaliano PLPolski SVSvenska TRTürkçe RUРусский PTPortuguês IDBahasa Indonesia MSBahasa Melayu THภาษาไทย VITiếng Việt JA日本語 KO한국어 ZH简体中文 ZH繁體中文 ARالعربية
TradingView
Ticker Trading Ideas Educational Ideas Scripts People
Profile Profile Settings Account and Billing My Support Tickets Contact Support Ideas Published Followers Following Sign Out Go PRO Go PRO 30-day Free Trial Go PRO Early
US Stocks Healthcare Biotechnology & Medical Research

ZYNERBA PHARMACEUTICALS INC NASDAQ:​ZYNE

 
     
 
     
Prev
 
Open
 
Volume
 
1 Day Range
  -  
EPS
 
Mkt Cap
 
PE
 
Div Yield
 
Overview Ideas Technicals
Popular Today
Popular Today
Popular All Time
Newest
Charts and Videos
Charts and Videos
Charts
Videos
Expand Chart

Technicals

Profile

Financials

Price History
Average Volume (10 day) ---
Beta - 1 Year ---
Price - 52 Week High ---
Price - 52 Week Low ---
Valuation
Enterprise Value/EBITDA, TTM ---
Enterprise Value, FQ ---
Market Cap - Basic ---
Number of Employees ---
Number of Shareholders ---
Price/Earnings, TTM ---
Price/Revenue, TTM ---
Price/Book Ratio, FY ---
Price/Sales Ratio, FY ---
Dividends
Dividends Paid, FY ---
Dividends per Share, FQ ---
Expected Annual Dividends ---
Dividends Yield ---
Margins
Net Margin, TTM ---
Gross Margin, TTM ---
Operating Margin, TTM ---
Pretax Margin, TTM ---
Balance Sheet
Current Ratio, FQ ---
Debt to Equity, FQ ---
Net Debt, FQ ---
Quick Ratio, FQ ---
Total Assets, FQ ---
Total Debt, FQ ---
Income Statement
Basic EPS, Net Income ---
Earnings per Share, Basic, TTM ---
EBITDA, TTM ---
Gross Profit, FY ---
Last Annual EPS ---
Last Annual Revenue, FY ---
Net Income, FY ---
Total Revenue, FY ---
Free Cash Flow, TTM ---
Operating Metrics
Return on Assets, TTM ---
Return on Equity, TTM ---
Return on Invested Capital, TTM ---
Revenue per Employee, TTM ---

News

nalinakshi nalinakshi ZYNE, D,
ZYNE: consolidating in lower range
15 0 3
ZYNE, D
consolidating in lower range

The company is currently in Phase II testing of ZYN002 for treatment of refractory epilepsy and osteoarthritis. It’s also in Phase I testing of ZYN002 for treatment of Fragile X syndrome. ZYN001 is still in preclinical testing for multiple indications as well. Shares of ZYNE stumbled at the start of 2017 as the company announced a 2.8 million-share offering ...

Community & Tools
House Rules Moderators People Chat Stock Screener Forex Screener Crypto Screener Economic Calendar AppStore
For Business
Website & Broker Solutions Widgets Charting Library Trading Terminal Brokerage Integration Advertising Referral Program Content Streams & RSS
Support
Contact Support Status Page Blog Feature Request Help & Wiki FAQ Contacts
About
How It Works Features Compare Plans Press Terms of Use Risk Warning Privacy Policy Cookies Policy
© 2018 TradingView
Stock Charts & Forex Charts
Made with
From the creators of MultiCharts
Select market data provided by ICE Data services
EN English (IN)
EN English
EN English (UK)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
SV Svenska
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
ZH 繁體中文
AR العربية
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing My Support Tickets Contact Support Ideas Published Followers Following Private Messages Chat Sign Out
Go PRO Go PRO 30-day Free Trial Go PRO Early
Browse
Video